Efficacy and safety of abobotulinumtoxinA in spastic lower limb: Randomized trial and extension

Conclusions:
In chronic hemiparesis, single abobotulinumtoxinA (Dysport Ipsen) administration reduced muscle tone. Repeated administration over a year was well-tolerated and improved walking speed and likelihood of achieving community ambulation.

Clinicaltrial.gov identifiers:
NCT01249404, NCT01251367.

Classification of evidence:
The double-blind phase of this study provides Class I evidence that for adults with chronic spastic hemiparesis, a single abobotulinumtoxinA injection reduces lower extremity muscle tone.

Source: Neurology - November 27, 2017 Category: Neurology Authors: Gracies, J.-M., Esquenazi, A., Brashear, A., Banach, M., Kocer, S., Jech, R., Khatkova, S., Benetin, J., Vecchio, M., McAllister, P., Ilkowski, J., Ochudlo, S., Catus, F., Grandoulier, A. S., Vilain, C., Picaut, P., On behalf of the International Abobotul Tags: Gait disorders/ataxia, Botulinum toxin, All Clinical trials ARTICLE Source Type: research